We are focused on finding and implementing solutions to medical problems
to provide meaningful answers for long term health. This pursuit is our mission - our passion.
Research
Mitokine is currently developing effective new diabetes treatments. We have shown that our main product, normally made with insulin, increases the number of insulin producing cells and protects them, suggesting it is a critical component of glucose management. Work from a Toronto research team, published June 2011 in PNAS, substantiates these results.
Management Team
We have assembled a management team that couples exceptional scientific capability with strong business skills. The founder and Chief Scientific Officer, Dr. Brooke Ligon M.D. Ph. D is a board certified Neurologist and did her dissertation at Tufts in Neuroscience. Her dissertation, and subsequent work, is the basis for Mitokine’s intellectual property. The Interim CEO, Paul J. Myer, has significant experience in the technology sector. Scientific and business advisory board members support the management team.
Mission
Mitokine Bioscience was founded to impact diabetes care by developing a promising new treatment. Since opening in 2006, our company has maintained a commitment to innovative research that solves medical problems and improves the daily lives of patients. Our current focus is on effective treatments that restore normal mechanisms of glucose management, potentially freeing patients of insulin injections.
Contact Us
Interested in learning more? Feel free to contact us.